Objective To observe the clinical efficacy and toxic and side effects of GP regimen or NX regimen in patients with recurrent metastatic triple negative breast cancer.Methods Between January 1, 2015 and December 31, 2017, 96 patients with recurrent and metastatic triple negative breast cancer who had previously received anthracycline or taxane treatment were selected from our hospital. They were randomly divided into two groups: 48 patients in the GP group and 48 in the NX group. The GP group was given the GP regimen (gemcitabine plus cisplatin); and the NX group was given the NX regimen (vinorelbine plus capecitabine). All patients had treatment for a total of 6 cycles. The primary study endpoint was objective response rate (ORR) and disease control rate (DCR), and the secondary study endpoint was time to tumor progression (TTP) and drug toxicity.Results The ORR and DCR in the NX group were higher than in the GP group, but there was no significant difference (P>0.05). The TTP in the GP group was slightly higher than in the NX group, but the difference was not statistically significant (P>0.05). The incidence rates of thrombocytopenia, gastrointestinal reactions and renal impairment were higher in the GP group than in the NX group (P<0.05). The incidence rate of hand-foot syndrome in the NX group was higher than in the GP group (P<0.05).Conclusion The GP or NX regimen had the same effects on the recurrent metastatic triple negative breast cancer. Both had tolerated adverse reactions and high safety. Both can be selected individually according to the tolerance of patients.